文献速递临床试验与 GCP流行病学与生物统计

平衡液与0.9%生理盐水对危重患者死亡率的影响:BaSICS随机临床试验

Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-08-10

BaSICS是在巴西75个ICU开展的双盲析因随机临床试验,纳入需液体复苏且预计ICU停留超过24小时的危重患者。

要点

  • 危重患者使用平衡液较0.9%生理盐水未显著降低90天死亡率
  • 两种液体均未见非预期的治疗相关严重不良事件

核心结论

  • 在需要液体复苏的危重患者中,使用平衡液较0.9%生理盐水未显著降低90天死亡率,结果不支持使用该平衡液。

研究设计与样本

  • 双盲析因随机临床试验,在巴西75个ICU开展,2017年5月29日至2020年3月2日随机入组。
  • 纳入ICU内至少1项不良结局危险因素、需至少1次液体扩容且预计ICU停留超过24小时的患者。
  • 患者同时按液体类型与输注速度两个因素随机,本文报告液体类型比较结果。

主要发现

  • 入组时平均年龄61.1岁(SD 17),女性占44.2%,计划外科入院占48.4%。
  • 60.6%存在低血压或使用血管升压药,44.3%入组时需机械通气。
  • 两组入组后第一天液体量中位数均为1.5 L。

关键数值与推荐

  • 两组均未见非预期的治疗相关严重不良事件。

临床怎么用

  • 危重患者液体复苏时,选择平衡液而非0.9%生理盐水未见90天生存获益。
  • 该结果不支持以改善90天死亡率目的常规选用本研究所用平衡液。

局限性

  • 研究在巴西75个ICU开展,外推至其他医疗体系需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury. OBJECTIVE: To determine the effect of a balanced solution vs saline solution (0.9% sodium chloride) on 90-day survival in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, factorial, randomized clinical trial conducted at 75 ICUs in Brazil. Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020. Patients were randomized to 2 different fluid types (a balanced solution vs saline solution reported in this article) and 2 different infusion rates (reported separately). INTERVENTIONS: Patients were randomly assigned 1:1 to receive either a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids. MAIN OUTCOMES AND MEASURES: The primary outcome was 90-day survival. RESULTS: Among 11 052 patients who were randomized, 10 520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women). There was no significant interaction between the 2 interventions (fluid type and infusion speed; P = .98). Planned surgical admissions represented 48.4% of all patients. Of all the patients, 60.6% had hypotension or vasopressor use and 44.3% required mechanical ventilation at enrollment. Patients in both groups received a median of 1.5 L of fluid during the first day after enrollment. By day 90, 1381 of 5230 patients (26.4%) assigned to a balanced solution died vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.90-1.05]; P = .47). There were no unexpected treatment-related severe adverse events in either group. CONCLUSION AND RELEVANCE: Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality. The findings do not support the use of this balanced solution. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02875873.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Zampieri FG, Machado FR, Biondi RS, et al. Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. JAMA. 2021. PMID: 34375394. doi:10.1001/jama.2021.11684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。